• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Non-severe tuberculosis in children can be treated with a shorter 4-month regimen

byDavid XiangandHarsh Shah
March 16, 2022
in Chronic Disease, Imaging and Intervention, Pediatrics, Public Health
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. For children with non-severe tuberculosis, 4 months of antituberculosis treatments was non-inferior to 6 months of antituberculosis treatments.

2. For children with non-severe tuberculosis, a shorter treatment regimen did not significantly change the frequency of adverse events.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Tuberculosis affects more than 1 million children annually with a mortality rate of about 20%. However, children typically have non-severe, smear-negative tuberculosis compared to adults, but current guidelines recommend 6 months of antituberculosis treatment in children, which is the same length of time as treatment in adults. Therefore, there is a gap in knowledge as to understanding whether 4 months of antituberculosis treatment would be as effective as 6 months of treatment in children with non-severe, smear-negative, drug-susceptible tuberculosis. This study found that 4 months of antituberculosis treatment was non-inferior to 6 months of antituberculosis treatment in children with non-severe tuberculosis. This study was limited by being an open-label trial which can lead to more frequent treatment extensions in the four-month group, as well as the generalizability of the results to settings where chest radiographs are not available for characterizing non-severe tuberculosis.  Nevertheless, these study’s findings are significant, as they demonstrate that 4 months of antituberculosis treatment is effective for treating children with non-severe, drug-susceptible, smear-negative tuberculosis.

Click to read the study in NEJM

Relevant Reading: Childhood Tuberculosis — Time for Shorter and Differentiated Treatment

In-Depth [randomized control trial]: This open-label, treatment-shortening, noninferiority trial studied 1204 children with non-severe and symptomatic tuberculosis in Uganda, Zambia, South Africa, and India from July 2016 to July 2018. Patients who were younger than 16 years of age who had symptomatic non-severe and smear-negative tuberculosis were included in the study. Non-severe tuberculosis was characterized as respiratory tuberculosis confined to one lobe with no cavities, no signs of miliary tuberculosis, no complex pleural effusion, and no clinically significant airway obstruction. Patients who did not fit these criteria were excluded from the study. Patients were either assigned to receive 4 months of antituberculosis treatment or the standard 6 months of treatment using WHO-recommended pediatric doses. The primary outcome was unfavorable status, a composite of treatment failure, change, a restart of treatment, or tuberculosis recurrence by 72 weeks. The primary safety outcome was an adverse event of grade 3 or higher during treatment and up to 30 days after treatment. Outcomes in the primary analysis were conducted on modified intention-to-treat population protocols and log-rank tests and Cox proportional-hazards models. Based on the analysis, the noninferiority of 4 months of antituberculosis treatment was consistent across the intention-to-treat, per-protocol, and key secondary analyses. An unfavorable outcome was reported in 3% of the 4-month group and 3% in the 6-month group (95% confidence interval [CI], -2.3 to 1.6). There were no significant between-group differences in the risks of an unfavorable status (hazard ratio [HR], 0.88; 95% CI, 0.45 to 1.72) and no significant between-group differences in risk of death (HR, 0.63; 95% CI, 0.31 to 1.30). Moreover, 8% of participants had an adverse event of grade 3 or higher, all but 2 of which occurred within the first 8 weeks when the treatments were the same in the two groups. Overall, this study demonstrated 4 months of antituberculosis treatment was non-inferior to 6 months of antituberculosis treatment in children with non-severe tuberculosis in Africa and India. This encourages a stratified therapeutic approach to drug-susceptible non-severe tuberculosis in children.

RELATED REPORTS

Wellness Check: Nutrition

Melatonin improves sleep onset in children with autism spectrum disorder

Wellness Check: Sleep

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Africaantituberculosis treatmentchildrenindiatreatment regimentuberculosis
Previous Post

Effectiveness of Covid-19 vaccines waned over timer in North Carolina

Next Post

Low- and no-calorie sweetened beverages associated with reduced body weight compared to sugar-sweetened beverages: a systematic review and meta-analysis

RelatedReports

Improved glycemic control in type 1 diabetics on very low-carbohydrate diets
Wellness

Wellness Check: Nutrition

January 26, 2023
Parents with poor sleep quality report sleep problems in kids
Pediatrics

Melatonin improves sleep onset in children with autism spectrum disorder

January 23, 2023
Decline in adolescent sleep duration over past 20 years
Wellness

Wellness Check: Sleep

January 19, 2023
Shorter moxifloxacin-containing regimens ineffective for treating TB [REMoxTB trial]
Chronic Disease

Oral BPaLM regimen is noninferior to standard of care for rifampin-resistant tuberculosis

January 4, 2023
Next Post
Added sugar intake associated with mortality from cardiovascular disease

Low- and no-calorie sweetened beverages associated with reduced body weight compared to sugar-sweetened beverages: a systematic review and meta-analysis

Garadacimab significantly reduces frequency of hereditary angioedema exacerbations

Patients with low back pain or pain at multiple sites at highest risk for chronic opioid use

Wellness Check: Addictions

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Higher body mass index may be associated with altered vitamin D levels and metabolism
  • #VisualAbstract: Torsemide does not provide additional decrease in mortality compared to furosemide among patients hospitalized for heart failure
  • Community-based adult vision screening program increases access to eye care
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options